FDA's Panobinostat Approval Ushers in New Class of Drug to Treat Multiple Myeloma
March 5th 2015The FDA's approval of panobinostat (Farydak) for multiple myeloma, the first histone deacetylase (HDAC) inhibitor to be approved in this space, provides a new option and new hope for patients with this disease, Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation, said.
A Voice for Women and Patients: Joan Lunden Shares Her Breast Cancer Journey
March 2nd 2015With a career as remarkable and distinguished as Joan Lunden's, it's really no surprise that she took on her latest challenge-a diagnosis of triple-negative breast cancer-with such determination and grace.
Dixon Questions Value of Chemoprevention With Tamoxifen
March 2nd 2015The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who discussed his position at the 32nd Annual Miami Breast Cancer Conference on Sunday.
For Some With Intermediate-Risk Prostate Cancer, Active Surveillance May Not Be Enough
February 23rd 2015The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients, according to results of a new study, the first to examine long-term outcomes of patients with low- versus intermediate-risk prostate cancer who have been managed with this conservative approach to care.
Ovarian Suppression Emerges as Practice-Changing Option for Premenopausal Breast Cancer Patients
February 20th 2015Women with HR-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent- tamoxifen compared with standard tamoxifen alone, according to results from the phase III SOFT trial.
Physicians Less Likely to Report Cancer Treatment Toxicities Than Their Patients
February 19th 2015A study involving more than 1000 patients enrolled in randomized clinical trials has found that patient and physician assessment of treatment toxicities can vary greatly, and they are frequently under-reported by physicians.
New Medicare Payment Model to Reward Coordinated, Patient-Centered Cancer Care
February 18th 2015The Center for Medicare & Medicaid Services (CMS) has announced a new initiative which it hopes will improve the coordination and quality of cancer care for Medicare patients with cancer while also reducing costs.
Hormone Replacement Therapy Associated with Increased Ovarian Cancer Risk
February 17th 2015A new analysis has shown that taking hormone replacement therapy to alleviate symptoms associated with menopause significantly increases the risk of developing the two most common types of ovarian cancer, even if the therapy is only taken for a few years.
Study Finds It's Not Cancer Patients Who Push for Unnecessary Tests and Treatments
February 13th 2015Although some physicians may blame patient demands for the increase in medical costs, a new study has shown that cancer patients rarely push their doctor to run unnecessary tests and treatments.
MMRF Offers Online CE for Nurses and Other Healthcare Professionals
February 11th 2015The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers.
Palbociclib Approval Will Improve Quality of Life for Late-Stage Breast Cancer Patients
February 6th 2015The big difference in progression-free survival seen in pivotal trial data propelled palbociclib to its accelerated FDA approval for the treatment of metastatic breast cancer, bringing with it the potential for the drug to quickly become adapted as the new standard of care, Brian Wojciechowski, MD, said.